Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 151–175 of 484 studies in Disparities · free to read (page 7 of 20) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 484 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Disparities” covers

Disparities — Differences in dementia risk, diagnosis and care across race, ethnicity, income, geography and sex.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Long-term exposure to PM 2.5 , NO 2 , and/or BC in Denmark were associated with mortality beyond cardiorespiratory diseases, including diabetes, dementia, psychiatric disorders, asthma, and ALRI. 5 key findings →

Participants: 803,881 Evidence: moderate

Numerous tools for assessment of cognitive impairment in low-literacy settings have been developed, and tools developed for use in high-income countries have also been validated in low-literacy settings. 2 key findings →

Design: meta-analysis Evidence: high

PIM use may be higher in dementia patients and their informal caregivers compared with the general older adult population. 5 key findings →

Participants: 566 Evidence: low

Systemic racism leads to racial/ethnic residential segregation, which can result in health inequities. 3 key findings →

Participants: 4,616 Evidence: low

Use of Feeding Tubes Among Hospitalized Older Adults With Dementia

✓ Peer-reviewed alzhub usefulness score 57 out of 100. JAMA Network Open 2025-02-20

Among 143 331 older adults with dementia (83 536 [58.3%] female; mean [SD] age, 83.8 [7.5] years), 1312 (0.9%) received a feeding tube in hospital and 142 019 (99.1%) did not. 5 key findings →

Design: cohort study Evidence: moderate

Dementia poses a significant global health challenge for both clinicians and patients, impacting millions of individuals worldwide, yet its early diagnosis remains underexplored. 2 key findings →

Design: meta-analysis Participants: 415 Evidence: high

Cognitive impairment in the U.S.: Lifetime risk, age at onset, and years impaired

✓ Peer-reviewed alzhub usefulness score 56 out of 100. SSM - population health 2020-03-31

Prior studies have analyzed the burden of cognitive impairment, but often use potentially biased prevalence-based methods or measure only years lived with impairment, without estimating other relevant metrics. 3 key findings →

Participants: 29,304 Evidence: low

Relative to white caregivers, blacks more often provided in excess of 40 hr of care per week (54.3% vs 38.6%) and more often cared for an older adult with dementia (27.1% vs 20.7%) who was living below the federal poverty line (31.7% vs 11.9%) or was Medicaid-eligible (42.2% vs 11.8%). 1 key finding →

Participants: 992 Evidence: low

Across Latin American and Caribbean countries (LACs), the fight against dementia faces pressing challenges, such as heterogeneity, diversity, political instability, and socioeconomic disparities. 5 key findings →

Evidence: low

Prevalent hemodialysis patients demonstrate significant cognitive decline, particularly within tests of executive function. 5 key findings →

Design: longitudinal study Evidence: moderate

In contrast to observations in individuals not treated with CART, we found no relationship between CSF markers and neurological status in this CART-using cohort with advanced HIV/AIDS. 2 key findings →

Design: cohort study Participants: 106 Evidence: moderate

Older patients on hemodialysis are at substantial risk of diagnosis with dementia and Alzheimer's disease, and carrying these diagnoses is associated with a twofold higher mortality. 4 key findings →

Participants: 356,668 Evidence: low

This analysis combining data from two health systems shows that area deprivation is an independent risk factor for cognitive dysfunction in older adults. 3 key findings →

Design: cross-sectional Participants: 5,186 Evidence: moderate

Attenuation of racial inequalities in older age can be extended to cognitive outcomes, which probably reflects selective survival. 1 key finding →

Design: cross-sectional Participants: 3,875 Evidence: moderate

The rising age of the global population has made Alzheimer's disease and related dementias (ADRD) a critical public health problem, with significant health-related disparities observed between rural and urban areas. 1 key finding →

Design: cohort study Evidence: moderate

This study presents findings from IDEA Café, for older adults aged 50 and older living with early dementia, dementia, Alzheimer’s Disease or cognitive impairment (ED/CI) with no informal caregiver or care partner. 2 key findings →

Design: randomized controlled trial Participants: 15 Evidence: high

AF is associated with greater cognitive decline and increased risk of dementia, independent of ischemic stroke. 5 key findings →

Participants: 515 Evidence: low

Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Acta neuropathologica 2018-12-03

TAR DNA-binding protein 43 (TDP-43) aggregation is the most common pathological hallmark in frontotemporal dementia (FTD) and characterizes nearly all patients with motor neuron disease (MND). 3 key findings →

Participants: 17 Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events